Background and Aims: Outcomes of cessation of anti-TNF therapy for Crohn's disease (CD) in clinical and/or endoscopic remission in routine clinical practice is uncertain. This study aimed to evaluate clinical outcomes and factors associated with relapse in CD patients following formal disease assessment and elective anti-TNF withdrawal. Methods: Prospective observational study of CD patients in whom anti-TNF therapy was stopped electively after ≥12months and follow-up of ≥6months. Investigations at assessment prior to cessation included ≥1 of clinical assessment, endoscopic and/or imaging. Relapse was defined as recurrent symptoms of CD requiring medical or surgical therapy. Results: Eighty-six patients received anti-TNF for a median duration of 23 (12-80) months for severe active luminal (70%), fistulating perianal (25.5%) and other fistulating disease (4.5%). Relapse rates at 90,180 and 365days were 4.7%, 18.6% and 36%, respectively. If anti-TNF dose escalation occurred 6months prior to withdrawal, 88% (7/8) relapsed. Based on multivariate analysis, risk factors for relapse include ileocolonic disease at diagnosis and previous anti-TNF therapy. An elevated faecal calprotectin (FC) is likely to predict relapse (p=0.02), with a PPV of 66.7% at >50μg/g. Of 36 patients who relapsed, 31 were retreated with anti-TNF, with an overall recapture rate of 93%.
Introduction
Anti-tumour necrosis factor alpha (TNFα) antibodies have made a major impact in the treatment of Crohn's disease as agents to induce and maintain remission. [1] [2] [3] [4] Scheduled maintenance treatment is associated with improved quality of life, fewer hospitalisations and higher rates of mucosal healing than episodic treatment. 5 Maintenance therapy for up to 20weeks also improves patient-reported outcomes and indirect, productivity-related costs. 6 The optimum duration of therapy and strategies for drug withdrawal remain unclear. There are reasons why patients and clinicians may consider elective withdrawal of therapy, including concern about long-term toxicity and cost. The Technology Appraisal by the UK National Institute for Health and Clinical Excellence (NICE) suggests that treatment with infliximab should only be continued where there is clear evidence of ongoing active disease-with withdrawal from treatment considered for all patients in stable clinical remission, and retreatment for people whose disease relapses after treatment is stopped. 7 It is not clear how such guidance should be translated into everyday clinical practice. In particular, there is little information about how assessment might be undertaken, the outcome following elective withdrawal and parameters which might indicate a higher risk of relapse on treatment withdrawal or act as an indication for continued treatment. Results from the multi-centre STORI trial 8 and from the more recent study by Molnar et al. 9 have suggested a relapse rate of approximately 50% following elective treatment withdrawal. This study is the first UK experience of elective withdrawal of anti TNFα agents following planned assessment.
Methods

Patients
This was a prospective observational study conducted across four large IBD centres in the Yorkshire and the Humber Region of the United Kingdom, covering a population of approximately 2 million. Eighty-six patients with Crohn's disease in whom anti-TNF therapy was discontinued electively following a planned assessment were included in the study. Patients were included if they were aged 18years or over and had undergone treatment with the anti-TNF agents, infliximab ("Remicade", Merck & Co) or adalimumab ("Humira", Abbvie). Infliximab was administered as an induction regimen of 5mg/kg by intravenous infusion at 0, 2 and 6weeks followed by maintenance treatment of 5mg/kg every 8weeks for a minimum of 12months. Adalimumab was administered as an induction regime of 160mg followed by 80mg after 2weeks by sub-cutaneous injection (n=10) or 80mg then 40mg (n=1) followed by maintenance treatment of 40mg every other week for a minimum of 12months. Instances of escalation of treatment regimens were recorded and comprised reduction of the planned dose interval or increase in dose from the above regimes. The median follow up post anti TNF cessation was 510days (365-2160 days). Further baseline characteristics of patients included in the study are shown in Table 1 . Of those who remained in remission throughout the study, the median follow-up was 495days (365-2160).
Assessment of disease
Formal assessment was undertaken prior to cessation of anti-TNF therapy. Assessment comprised one or more of the following: a clinical assessment either by physician's global assessment or Harvey Bradshaw Index (HBI), C-reactive protein, faecal calprotectin (FC) colonoscopy, magnetic resonance enterography (MRE), small bowel meal (SBM), wireless capsule endoscopy of the small bowel (SB WCE), wireless capsule endoscopy of the colon (LB WCE) and, in patients with perianal disease, perianal MRI scan. Anti-TNF agents were withdrawn when disease was deemed to be inactive on investigations or on the basis of the physician's global assessment. Relapse was defined as recurrent symptoms of Crohn's disease requiring an escalation in medical therapy or surgery.
In assessing the differences in outcome depending on the method of assessment and the site of disease, two overlapping sub-groups were identified for further analysis (Table 2) :(a)Endoscopy subgroup: those where the affected area of intestine had been directly visualised by endoscopy: colonic disease required colonoscopy or capsule endoscopy of the large bowel. Ileocolonic disease required colonoscopy or capsule endoscopy of the large bowel plus small bowel wireless capsule endoscopy and ileal disease required small bowel wireless capsule endoscopy. (b)Imaging sub-group: those undergoing investigation but where the affected area of intestine had been visualised by endoscopy or assessed radiologically (n=50): criteria as above in colonic disease (n=16) but MRE or SBM allowed for those with ileal (n=7) or ileocolonic (n=27) disease instead of SB WCE.
Statistical analysis
Statistical analysis was performed using the R open source statistical computing software (version 3.0.2, The R Foundation for Statistical Computing with the survival and Party packages). Multivariate analyses of all input factors in relation to relapse were examined using a binomial logistic regression model. Factors that had multiple missing data items were eliminated to give a total of 75 case, and input factors with multiple missing values were also eliminated from the analysis. Odds ratios with p values and 95% confidence intervals for the factors were calculated. Comparisons between two groups, where appropriate, were analysed using the Fisher's exact test or Pearson's Chi-square test. Kaplan-Meier estimates were used to determine disease free survival and time-to-relapse. Univariate analysis was performed separately on the subgroup of patients with faecal calprotectin (FC) concentration available. A receiver-operating characteristic (ROC) curve was performed to guide a cutoff concentration for FC to determine sensitivity and specificity.
Results
Indications for anti-TNF antibody treatment and treatment regime
The indications for anti-TNF treatment are shown in Table 1 . 75 (87%) patients received infliximab and 11 (13%) adalimumab. The median treatment duration with anti-TNF was 23months (range 12-80 months). Seventy-six patients (88%) were receiving immunomodulators following anti-TNF withdrawal, compared to 69/86 (80%) of patients at the start of anti-TNF therapy.
Assessment of disease activity
In addition to routine clinical assessment by HBI, the assessment of disease activity comprised one or more of colonoscopy (63), LB WCE (4), MRE (25), MRI perianal (16), SB WCE (5), SBM (4), white cell scan (2), examination under anaesthesia (1), FC (26) and CRP (80). Of the 76 people who had endoscopic or radiological investigations, 31 had 1 test, 43 had 2 tests and 2 had 3 tests. The assessment practice changed following the publication of the NICE technology appraisal in May 2010. Before this change, 8/15 (53%) of patients stopping anti-TNF underwent clinical assessment alone to assess disease activity. After May 2010, this fell to 2/71 (3%; p <0.001) with (97%) using imaging and endoscopy for reassessment.
Relapse following withdrawal of anti-TNF therapy
The relapse rates for all patients within 90,180 and 365days of withdrawal of anti-TNF therapy were 4/86 (4.7%), 16/86 (18.6%) and 31/86 (36%), respectively (Table 3) , with Kaplan-Meier estimate of survival without relapse over time for whole study cohort shown in Fig. 1 . The median time to relapse after anti-TNF cessation was 225days (42-1185 days). Relapse rates in the sub-group who received anti-TNF for the primary indication of perianal fistulating disease, within 90,180 and 365days, were 1/22 (4.5%), 3/22 (13.6%) and 6/22 (27.3%), respectively. 50/60 (83%) of those with luminal disease met the criteria for assessment to be included in the imaging sub-group, with relapse rates within 90,180 and 365days of 2/50 (4%), 11/50 (22%) and 20/50 (40%), respectively. In those assessed in the Endoscopy sub-group, the overall relapse rates were 1/16 (6.3%), 2/16 (12.5%) and 5/16 (31.3%) within 90,180 and 365days (Table 3) .
Retreatment with anti-TNF agents following elective withdrawal
Of the 36 patients who relapsed, 31 were retreated with an anti-TNF agent after median duration of 210days (range, 42-1185 days). Response was defined clinically by the supervising physician on the basis of significant and satisfactory improvement in symptoms. Three patients were lost to follow-up after moving region of care. Of the remaining 28 patients, 26 responded to initial retreatment with anti-TNF, with an overall recapture rate of 93%. A further 2 patients stopped anti-TNF due to side effects (neutropenia in both cases). Twenty-four of 26 (92%) of the remaining patients remained in remission at 1year following anti-TNF retreatment; 24/31 (77%) were retreated with the same anti-TNF as previously withdrawn, with a response rate of 20/23 (87%) with one patient lost to follow-up. There were no significant infusion reactions with anti-TNF retreatment. A further 7 were retreated with adalimumab, following infliximab withdrawal, and in this group 6/7 (86%) responded.
Predicting relapse
Multivariate analysis demonstrated the following factors to predict relapse at any point in follow-up period of study with odds ratio (95% CI), respectively, shown in factors identified as significant in the multivariate analysis were confirmed on a univariate basis using the log-rank test and visualised on Kaplan-Meier plots with respective log-rank p -values ( Fig. 2 ileocolonic disease vs. other sites; Fig. 3 previous anti-TNF therapy vs. no previous anti-TNF therapy; Fig. 4 previous anti-TNF dose escalation vs. no dose escalation; Fig. 5 FC ≤50μg /g or >50μg/g). A significant univariate difference was detected in FC between relapse (median 61.5μg/g) and non-relapse (median 33.5μg/g), with those who relapse having significantly higher FC at assessment (p=0.02, n=26, Wilcoxon rank sum test) (Fig. 6 ). An ROC curve for FC at assessment gave an area under the curve of 0.79 (Fig. 7) , which guided a threshold for FC at >50μg/g to be chosen for prediction of relapse, giving a positive predictive value of 66.7% (pre-test probability 38.5%). Of the 80 patients who had a CRP performed at assessment, 55 (69%) had a CRP≤5mg/L.
Eight patients had a dose escalation by increased dose or reduction in dose interval of anti-TNF, in the 6months prior to assessment for withdrawal. Of these, 7 (88%) relapsed despite having normal investigations (colonoscopy 6, MRE 3, perianal MRI 1) at the time of assessment.
Discussion
This is the first UK experience of elective withdrawal of anti-TNF agents in patients in established stable remission, demonstrating an overall relapse rate of 36% at 1year-lower than from other published series in Europe 8, 9 and Canada. 10 In the diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunopressors (STORI) study, 44% of patients relapsed at 12months, 8 but different outcomes following withdrawal of anti-TNF treatment were used in the other studies: 45% of patients requiring retreatment with anti-TNF agents within a year, 9 and 50% relapsing after a median of 477days from treatment withdrawal. 10 Importantly, the populations studied also differed. In the STORI study, two-thirds of patients did have abnormalities at endoscopy (CDEIS>0), and 12% had only received two infliximab infusions or fewer in the preceding 6months. 8 In the Hungarian study, in line with national regulations, infliximab was withdrawn electively when patients were in symptomatic remission-without further investigation. 9 In the Canadian, single-centre study, although all patients were in remission, they had treatment withdrawn for a number of reasons including patient and physician choice, pregnancy and loss of insurance. 10 In this UK multi-centre study, patients were electively withdrawn when in established remission-established clinically and with adjunctive endoscopic or radiologic assessment. Patients with perianal disease, excluded from the STORI and Molnar studies, are included in this study with a relapse rate the same as for those with luminal disease. The median duration of disease for this study was also shorter than for patients in the STORI study, suggesting that the relapse rate is similar in disease of shorter duration.
As with previous studies, 8,9,10 the current study is not a randomised trial of anti-TNF withdrawal and cannot confirm that withdrawal is associated with a higher relapse rate than continued treatment. In comparison with the relapse rates described following withdrawal of anti-TNF therapy, of patients maintained on . Kaplan-Meier estimate of survival without previous anti-TNF dose escalation compared to those with previous dose escalation. The log-rank test p value shows that the difference between the two survival curves is significant. Figure 5 . Kaplan-Meier estimate of survival without relapse following withdrawal of anti-TNF treatment (n=26) for those with faecal calprotectin at assessment prior to drug withdrawal >50μg/g compared with those with faecal calprotectin <50μg/g. Threshold based on ROC curve in Fig. 7 . The logrank test p value shows that the difference between the two survival curves is statistically significant. adalimumab in the Additional Long-Term Dosing With HUMIRA to Evaluate Sustained Remission and Efficacy in Crohn's Disease (ADHERE) study for 12months following response to adalimumab in the Crohn's Trial of the Fully Human Antibody Adalimumab for Remission Maintenance (CHARM) study, 11 the most stringent analysis showed that 22.8% of patients failed to maintain corticosteroid-free remission. Patients are concerned about the consequences of withdrawing anti-TNF treatment, 12 and this study adds to experience informing that discussion.
We have been unable to show that intensive assessment with combinations of endoscopy and MR enterography is associated with lower relapse rates. Molnar et al. 9 also reported no correlation between mucosal healing and the frequency or time to relapse. Louis 8 reported an increased odds ratio for relapse if ileocolonic lesions were seen at colonoscopy (CDEIS>0) was 2.3, but the relapse rate in those with normal colonoscopy is not given. Patients in that study did not have imaging of the small bowel proximal to the terminal ileum. 8 Faecal calprotectin (FC) may provide an accurate marker of mucosal healing 13 and act as a simple, non-invasive surrogate for more intensive assessments. The odds ratio for relapse in the STORI study was 2.5 with an FC>300μg/g. 8 In the current study, the significant association of FC with relapse, at the lower threshold level of >50μg/g, and despite the small number who had an FC assessment, also suggests that it may have a role in predicting relapse. This needs confirmation in a prospective study. FC was missing in over a quarter of cases in the STORI study. In our study, in patients undergoing radiological or endoscopic assessment, apparent mucosal healing was not associated with more prolonged remission.
In our study, only disease site and previous anti-TNF treatment were associated with an increased risk of relapse on multivariate analysis. Dose intensification has been identified as increasing the risk of relapse. 9 Our experience also suggested a higher risk in this group but the numbers were too small to confirm this. In practice, this group might be considered for management by an alternative strategy, such as extending the dose interval back to the standard interval, before considering withdrawal.
The efficacy of reintroduction of anti-TNF agents after withdrawal is important in assessing the relative merits of a treatment strategy of elective withdrawal or continued treatment. We observed a success rate of over 93% on reintroduction of either infliximab (with no infusion reactions) or adalimumab, with remission maintained at 1year in 92%. In the STORI study, infliximab reintroduction to 52 patients was successful in all of these, with no significant infusion reactions. 8 Elective withdrawal of anti-TNF therapy is therefore associated with a significant risk of relapse despite intensive endoscopic and radiological investigation. Based on our findings and previously published reports, patients and clinicians considering withdrawal of anti-TNF should discuss a relapse rate of between 36% and 44% at 1year following anti-TNF cessation, with high response rates on reintroduction of anti-TNF therapy on relapse up to 1year. In particular, due to the lower relapse rates reported in this study, a strategy of offering withdrawal of anti-TNF therapy to patients in established remission, with a normal faecal calprotectin, without previous dose escalation may be reasonably considered. However, a randomized controlled trial comparing this strategy with continuous therapy is required.
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